Prognostic value of MYC rearrangement in cases of B‐cell lymphoma, unclassifiable, with features intermediate between diffuse large B‐cell lymphoma and Burkitt lymphoma
暂无分享,去创建一个
M. Routbort | L. Medeiros | L. Fayad | P. Lin | R. Miranda | W. Qiao | P. Lennon | Peter Hu | Mar García | T. Dickason | Xumei Wang
[1] A. Bagg,et al. B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma , 2012 .
[2] L. Medeiros,et al. Residual monotypic plasma cells in patients with waldenstrom macroglobulinemia after therapy. , 2011, American journal of clinical pathology.
[3] Philip M Kluin,et al. Double-hit B-cell lymphomas. , 2011, Blood.
[4] S. Barrans,et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] A. Carbone,et al. B-cell lymphomas with features intermediate between distinct pathologic entities. From pathogenesis to pathology. , 2010, Human pathology.
[6] R. Gascoyne,et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. , 2009, Blood.
[7] R. Gascoyne,et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. , 2009, Blood.
[8] E. Obermann,et al. Aberrations of the MYC gene in unselected cases of diffuse large B-cell lymphoma are rare and unpredictable by morphological or immunohistochemical assessment , 2009, Journal of Clinical Pathology.
[9] N. Nakamura,et al. Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations , 2009, Haematologica.
[10] I. Miura,et al. Clinical significance of 8q24/c‐MYC translocation in diffuse large B‐cell lymphoma , 2009, Cancer science.
[11] R. Siebert,et al. Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge , 2008, Leukemia.
[12] A. Rosenwald,et al. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) , 2008, Leukemia.
[13] L. Medeiros,et al. Acute myeloid leukemia harboring t(8;21)(q22;q22): a heterogeneous disease with poor outcome in a subset of patients unrelated to secondary cytogenetic aberrations , 2008, Modern Pathology.
[14] P. Moreau,et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement , 2007, Haematologica.
[15] R. Zini,et al. High-grade B-cell lymphoma/leukemia associated with t(14;18) and 8q24/MYC rearrangement: a neoplasm of germinal center immunophenotype with poor prognosis , 2007, Haematologica.
[16] Kathryn A. O’Donnell,et al. The c-Myc target gene network. , 2006, Seminars in cancer biology.
[17] Richard Simon,et al. Molecular diagnosis of Burkitt's lymphoma. , 2006, The New England journal of medicine.
[18] R. Spang,et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. , 2006, The New England journal of medicine.
[19] H. Kantarjian,et al. Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia , 2006, Cancer.
[20] L. Medeiros,et al. Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis , 2006, Modern Pathology.
[21] G. Rassidakis,et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma associated with IgM paraprotein: A clinicopathologic study of 26 cases , 2005 .
[22] G. Rassidakis,et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma associated with IgM paraprotein. , 2005, American Journal of Clinical Pathology.
[23] R. Gascoyne,et al. Small noncleaved, non-Burkitt's (Burkit-Like) lymphoma: cytogenetics predict outcome and reflect clinical presentation. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.